GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Short Interest

Transgene (XPAR:TNG) Short Interest


View and export this data going back to 1998. Start your Free Trial

What is Transgene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Transgene's Short Interest

For the Biotechnology subindustry, Transgene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's Short Interest distribution charts can be found below:

* The bar in red indicates where Transgene's Short Interest falls into.


Transgene (XPAR:TNG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Short Interest
Comparable Companies
XPAR:ADOC XPAR:DBV XPAR:MAAT XPAR:IVA XPAR:AELIS XPAR:OSE XPAR:ALVAL XPAR:GNFT XPAR:GNRO XPAR:IPH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TGNA:Germany
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400
Website
https://www.transgene.fr
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines